Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
Global Coronary Artery Bypass Graft (CABG) market size was valued at USD 126 million in 2024. The market is projected to grow from USD 131 million in 2025 to USD 162 million by 2031, exhibiting a CAGR of 3.8% during the forecast period.
Coronary artery bypass graft surgery is a critical cardiovascular procedure that redirects blood flow around blocked coronary arteries using transplanted blood vessels. This surgical intervention primarily utilizes three types of grafts: saphenous vein grafts (accounting for approximately 70% of procedures), internal thoracic artery grafts, and other vessel alternatives. The procedure remains the gold standard for treating multi-vessel coronary artery disease despite advancements in percutaneous interventions.
The market growth is driven by an aging population with increasing prevalence of coronary artery disease, particularly in developed regions. North America currently dominates with over 35% market share due to high healthcare expenditure and advanced surgical infrastructure, followed by Europe and Asia-Pacific collectively representing about 55% of global demand. While traditional CABG procedures maintain market leadership, innovations in minimally invasive and off-pump techniques are gaining traction among surgeons seeking to reduce patient recovery times.
Rising Prevalence of Coronary Artery Disease
The global CABG market is primarily driven by the increasing prevalence of coronary artery disease (CAD), which affects approximately 18 million adults worldwide. With aging populations and lifestyle factors contributing to higher CAD rates, the demand for bypass surgeries continues to grow at a steady pace of 4-5% annually.
Technological Advancements in Surgical Techniques
Innovations such as minimally invasive CABG and robotic-assisted surgeries have significantly improved patient outcomes and reduced recovery times. These advancements have expanded the eligible patient pool by approximately 15-20% in developed markets since 2020.
The global off-pump CABG segment now accounts for nearly 35% of all procedures, demonstrating strong preference for techniques that reduce neurological complications
Healthcare infrastructure development in emerging economies has further propelled market growth, with countries like India and China seeing 8-10% annual increases in CABG procedure volumes.
MARKET CHALLENGES
High Procedure Costs and Reimbursement Issues
CABG procedures remain expensive, with average costs ranging from $40,000 to $100,000 per surgery depending on complexity. Many healthcare systems face challenges in providing adequate reimbursement coverage, particularly for advanced techniques.
Other Challenges
Competition from Alternative Therapies
PCI (Percutaneous Coronary Intervention) procedures continue to capture market share, particularly for less complex cases, with approximately 45% of CAD patients now receiving stents instead of bypass surgery.
Specialist Shortages
There remains a global shortage of qualified cardiothoracic surgeons, particularly in developing countries where the ratio is as low as 1 specialist per 10 million population.
Preference for Minimally Invasive Alternatives
The growth of transcatheter and hybrid procedures has impacted conventional CABG volumes, particularly in Europe where these techniques account for nearly 20% of revascularization procedures. Patient concerns about sternotomy recovery times have also contributed to slower growth in some segments.
Expansion in Emerging Markets
Developing healthcare infrastructure in Asia-Pacific and Latin America presents significant opportunities, with projected CABG procedure growth rates of 7-9% annually through 2030. Local production of grafts and surgical instruments is helping reduce costs in these regions.
Innovations in Graft Materials
The development of bioengineered grafts and stem cell-enhanced conduits represents a promising frontier, with early clinical trials showing 85-90% patency rates comparable to traditional vein grafts.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Saphenous Vein Grafts dominate the market due to their superior availability and proven long-term patency rates. Internal Thoracic Artery Grafts are gaining traction among surgeons for their superior longevity in left anterior descending artery cases. The Other Grafts segment includes emerging alternatives like radial artery grafts which show promise in specific patient populations. |
| By Application |
|
Traditional CABG remains the gold standard for multi-vessel coronary disease treatment, preferred for its established efficacy. Nontraditional CABG applications are growing rapidly, particularly in minimally invasive and robotic-assisted surgeries that reduce recovery time. Medical Applications encompass diagnostic and monitoring technologies that enhance surgical outcomes, while Others include emerging hybrid procedures. |
| By End User |
|
Hospitals account for the majority of procedures due to their comprehensive cardiac care capabilities and intensive care infrastructure. Cardiac Centers are experiencing growth as specialized hubs for complex cardiovascular interventions. Ambulatory Surgical Centers are emerging as viable options for select CABG cases, driven by cost-efficiency and patient preference for shorter stays. |
| By Procedure Complexity |
|
Multi-Vessel procedures represent the most common complexity level, addressing advanced coronary artery disease. Single Vessel cases are declining with the rise of alternative treatments like stenting. Reoperative CABG presents unique challenges and opportunities, requiring specialized techniques and experienced surgical teams to manage complex anatomical situations. |
| By Surgical Approach |
|
On-Pump CABG continues to be widely used for its excellent surgical field control and proven outcomes. Off-Pump techniques are preferred for high-risk patients to avoid cardiopulmonary bypass complications. Minimally Invasive approaches are gaining momentum, offering reduced trauma and faster recovery times, with particular adoption in single-vessel and select multi-vessel cases. |
Consolidated Market Dominated by Top 5 Medical Device Giants
The global Coronary Artery Bypass Graft (CABG) market exhibits a consolidated structure with Medtronic, Getinge Group, and LivaNova collectively commanding over 65% market share. Medtronic maintains dominance through its comprehensive cardiovascular portfolio and strategic acquisitions, while Terumo Corporation has shown remarkable growth in Asia-Pacific markets with specialized graft technologies. Boston Scientific complements its stent offerings with innovative CABG solutions, particularly in minimally invasive procedures segment.
Niche players like Genesee Biomedical and Vitalitec focus on specialized surgical instruments for CABG procedures, whereas Edwards Lifesciences leads in biological grafts segment. Emerging players such as Novadaq Technologies (now part of Stryker) have introduced advanced imaging systems for graft assessment, capturing share in the North American market. Regional manufacturers like Sorin Group (now LivaNova) maintain strong positions in European cardiovascular markets through hospital partnerships.
List of Key Coronary Artery Bypass Graft (CABG) Companies ProfiledLivaNova PLC
Boston Scientific Corporation
Edwards Lifesciences Corporation
MAQUET Holding B.V. & Co. KG
Vitalitec International Inc.
Genesee Biomedical, Inc.
Sorin Group (LivaNova)
Guidant Corporation (now part of Boston Scientific)
Ethicon (Johnson & Johnson)
Abbott Cardiovascular
The global CABG market is experiencing steady growth, valued at $126 million in 2024 with projections reaching $162 million by 2031, reflecting a 3.8% CAGR. This expansion is primarily driven by increasing cardiovascular disease rates worldwide, particularly in aging populations. North America currently leads the market with 35% share, followed by Europe and Asia-Pacific collectively holding 55% market share. The procedure's effectiveness in treating coronary artery disease continues to make it a preferred intervention despite newer alternatives.
Other TrendsProduct Segment Dominance
Saphenous vein grafts maintain market leadership at 70% share, followed by internal thoracic artery grafts. The high success rates and relative ease of harvesting saphenous veins from patients' legs contribute to this dominance. Meanwhile, technological advancements in graft materials and preservation techniques are creating growth opportunities across other product segments.
Application Segment Analysis
Traditional CABG procedures continue to represent the largest application segment, though nontraditional approaches are gaining traction. The market sees increasing adoption of off-pump CABG techniques in certain patient populations, driven by reduced complication risks and shorter recovery periods compared to conventional on-pump procedures.
Competitive Landscape and Regional DevelopmentsThe CABG market remains consolidated, with the top five manufacturers controlling approximately 65% market share. Medtronic leads the competitive field, with other key players including Getinge Group, LivaNova, Terumo, and Boston Scientific. Asia-Pacific is emerging as the fastest-growing region, supported by improving healthcare infrastructure and rising disease awareness. Europe maintains strong adoption rates due to established reimbursement policies and high procedural volumes.
Regional Analysis: Coronary Artery Bypass Graft (CABG) MarketEurope
Europe represents the second-largest CABG market, characterized by universal healthcare systems and standardized quality protocols. Western European countries maintain high procedure volumes, with Germany and the UK hosting specialized cardiac centers of excellence. The region shows strong adoption of off-pump CABG techniques and emphasizes multidisciplinary team approaches. Eastern Europe is improving access with hospital modernization projects and EU-funded healthcare initiatives. Stringent regulatory frameworks ensure device safety while potentially slowing innovative technique adoption. Patients benefit from comprehensive postoperative care pathways and rehabilitation programs integrated with CABG procedures.
Asia-Pacific
The Asia-Pacific CABG market is experiencing rapid growth due to expanding healthcare access and rising coronary disease prevalence. Japan and Australia lead in CABG quality standards, while China and India show the fastest growth rates in procedure volumes. Urban medical centers offer advanced CABG techniques, though rural areas still face infrastructure challenges. The region benefits from cost-effective surgical options and domestically produced devices. Cultural perceptions about heart surgery and competing treatment modalities like angioplasty influence CABG adoption rates. Medical tourism for cardiac surgeries contributes to market development in several countries.
South America
South America's CABG market shows steady growth concentrated in major urban centers. Brazil and Argentina have well-established cardiac surgery programs, while other countries face resource limitations. Public hospitals handle significant CABG volumes, supplemented by private institutions catering to medical tourists. Economic factors influence the pace of technology adoption, with some countries prioritizing basic CABG access over advanced techniques. Regional cardiac societies work to standardize training and improve surgical outcomes across diverse healthcare systems.
Middle East & Africa
The Middle East & Africa demonstrates diverse CABG market dynamics, with Gulf states investing in state-of-the-art cardiac centers attracting international patients. South Africa has the most developed CABG infrastructure on the continent. Many regions face challenges including equipment shortages and limited specialist availability. Medical charities facilitate CABG access in underserved areas. The market shows potential for growth with hospital construction projects and international healthcare partnerships in several countries.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global Coronary Artery Bypass Graft market was valued at USD 126 million in 2024 and is expected to reach USD 162 million by 2031, growing at a CAGR of 3.8% during the forecast period.
-> Key players include Medtronic, TERUMO, Guidant, MAQUET, and Vitalitec, among others. Global top five manufacturers hold about 65% market share.
-> Key growth drivers include aging population, increasing prevalence of coronary artery disease, and advancements in surgical techniques.
-> North America dominates with over 35% market share, followed by Europe and Asia-Pacific collectively representing about 55% of global demand.
-> Main segments include saphenous vein grafts (70% share), internal thoracic artery grafts, and other graft types.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates